• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
EuroBioForum 2013 - Day 1 | Etienne Richer
 

EuroBioForum 2013 - Day 1 | Etienne Richer

on

  • 431 views

EuroBioForum 2013 2nd Annual Conference ...

EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013

=======================================

# NATIONAL PERSPECTIVES #

Canada:
Personalised Medicine: A Canadian Collaborative Perspective'

Dr Étienne Richer, Assistant Director at CIHR Institute of Genetics

=======================================

http://www.eurobioforum.eu

Statistics

Views

Total Views
431
Views on SlideShare
426
Embed Views
5

Actions

Likes
0
Downloads
2
Comments
0

1 Embed 5

http://www.eurobioforum.eu 5

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    EuroBioForum 2013 - Day 1 | Etienne Richer EuroBioForum 2013 - Day 1 | Etienne Richer Presentation Transcript

    • Personalized Medicine: ACanadian CollaborativePerspectiveMunich, May 27 2013Etienne Richer, PhDCIHR Institute of Genetics
    • As defined by the Personalized Medicine Working Group(Health Canada):Personalized medicine refers to the tailoring of preventative,diagnostic or therapeutic interventions to the characteristicsof an individual or population.It does not mean the creation of health interventionstargeted directly to an individual, but rather that the scientificadvancements that underpin personalized medicine providethe ability to classify individuals into sub-populations basedon their susceptibility to a disease, or response to a specifictreatment.This can allow for prevention/intervention strategiesand earlier and/or targeted interventions to improvehealth outcomes.Personalized “Stratified” Medicine/Health
    • CIHR and its Institutes
    • Enhance health outcomes through patientstratification approaches by integratingevidence-based medicine and precisiondiagnostics into clinical practiceDevelop and translate discoveriesBiomarkers,targets andgenomicsignaturesDiagnostics andinnovative devices(imaging and point ofcare devices) forclinical useSupport policy andpracticeImprove the evidencebase on how to assessand eventually integrateinnovative diagnosticsand therapeuticapproaches into practicePersonalized Medicine Initiative
    • Canadian Personalized MedicineStakeholder MapFederalPatient /ProfessionalGroupsProvinces &Territories IndustryResearchCIHR/NSERC/GenomeCanadaResearchPrioritiesNational LabStandardsProductR&DPMPRBProductSubmissionsSurveillanceCADTHHealth CanadaPHACNational PolicyInterestsProvincial &TerritorialResearchFormularyDiscussionsProvincial &Territorial LabStandardsT. Ryan Sigouin, Health Canada adapted by Inga Murawski CIHR-ICR and Etienne Richer CIHR-IGHealthcarePrioritiesINESSS
    • Building a National Framework• CIHR-Genome Canada Funding Opportunities• Pediatric cancer consortium• Rare Disease Consortium (FORGE)Evidence• Health Canada and provincial regulatorsengagement• International Policies for Research (IRDiRC)Regulatory andPolicy Challenge• SPOR networks-clinical trials• Networking initiatives in Canada• National Framework/ConsortiumNational Structure• Community-Based Primary Health CareInnovation Teams - CIHR Signature Initiative• Public OutreachOutreach• Data Harmonization/eHealth data• Computational Biology• National Asset MapData
    • 2010 Advancing Technology Innovationthrough Discovery Program ($6.5M)Finding of Rare Disease Genes in Canada (FORGE)• Goal: To rapidly identify disease-causing genesresponsible for rare genetic disorders that affect children inCanada• 132 rare disorders studied to dateThe Canadian Pediatric Cancer Genome Consortium• Goal: To rapidly identify cancer-causing genes, improvesurvival, and reduce long-term consequences for childrenwith brain, bone and blood cancersEvidence
    • 2012 Genomics and PersonalizedHealth $71 M ($142 M)Large Scale Research Projects ($5 + $5 M)• Demonstrate how omics-based research and technology cancontribute to a more evidence-based approach to health• Applications must demonstrate high potential for attainingeventual clinical utility and/or practical applicabilityLarge Scale GE3LS Projects• Including genomics: utility, clinical and comparativeeffectivenessResults will be known Spring 201317 teams fundedEvidence
    • Multidisciplinary Research TeamsFunded in 2012 ($29 M)EvidenceEmerging Team Grant – Rare Diseases ($17 M)• To enhance our understanding of the fundamental biology ofthese diseases, foster the application of that knowledge to theclinic or to populations (group 1), and/or address major healthservices/policy/economic/ethical, legal or social issueschallenges (group 2)• 5 teams funded (group 1); 4 teams funded (group 2)Childhood Cancer – Late Effects of Treatment ( $12 M)• Multidisciplinary teams address major late effects of cancertreatment, through stratification, reducing toxicity leading toenhanced survivorship, Quality of Life• 4 Teams funded
    • 2012 Bioinformatics andComputational Biology ($11 M)DataSmall-Scale Innovative Projects ($250K for 2 years)Large-Scale Applied Projects ($500K for 3 years)• Goal: to support the development (and access) of nextgeneration Bioinformatics and Computational Biology toolsand methodologies that will be required by the researchcommunity to deal with the influx of large amounts of dataproduced by modern genomics technologies
    • Engagement and Support StructureEngage Health Canada and Provincial Regulators• Organize workshops and meetings (May 2011, January 2012,March 2013)Regulatory andPolicy ChallengeNationalStructureDevelop National Infrastructure and Services• By continuing to develop a national infrastructure and services,including biobanks, networks, clinical trials, portals
    • Global Reach – Personalized MedicineRare Diseases CancerPersonalizedMedicine
    • • If only 1 Priority: Develop an innovative clinical trial designframework/specialized support unit• We are open for business…• Consider Canada (CIHR) as a friend who wants to play…Conclusions
    • Thank YouDr. Morag Park, Scientific Director ofCIHR’s Institute of Cancer Researchmpark.ic-icr@mcgill.caDr. Inga Murawski, Associate, StrategicInitiativesInga.murawski@mcgill.caDr. Paul Lasko, Scientific Director ofCIHR’s Institute of GeneticsPaul.lasko@mcgill.caDr. Etienne Richer, Assistant DirectorEtienne.richer@mcgill.ca